Sherna Madan
San Carlos, CANPI 1134242753
Payments from drug & device makers
Across 124 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$558
- Mannkind Corporation$410
- Novo Nordisk$361
- Lilly USA, LLC$357
- Amgen$336
- plus $785 from 13 others
What the payments were for
- Food & beverage$3,844100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $1,046 |
| AstraZeneca(2 entities) | 13 | $558 |
| Mannkind Corporation | 15 | $410 |
| Novo Nordisk | 19 | $361 |
| Lilly USA, LLC | 9 | $357 |
| Amgen(2 entities) | 11 | $336 |
| Corcept Therapeutics | 7 | $236 |
| Radius Health, Inc. | 5 | $192 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $43 |
| Novartis | 2 | $40 |
| Johnson & Johnson | 2 | $37 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Alfasigma USA, Inc. | 1 | $28 |
| CMP Pharma, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Insulet Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AfrezzaInsulin Regular, Human | 40 | $139,518 |
| JardianceEmpagliflozin | 55 | $77,197 |
| OzempicSemaglutide | 41 | $68,985 |
| TrulicityDulaglutide | 43 | $60,804 |
| MounjaroTirzepatide | 32 | $41,260 |
| XareltoRivaroxaban | 15 | $26,102 |
| ProcritEpoetin Alfa | 14 | $26,060 |
| FarxigaDapagliflozin Propanediol | 18 | $25,916 |
| EliquisApixaban | 15 | $16,968 |
| MyrbetriqMirabegron | 14 | $14,375 |
| Estradiol | 41 | $11,306 |
| Praluent PenAlirocumab | 12 | $7,649 |
| Estradiol (Twice Weekly)Estradiol | 68 | $6,896 |
| ProgesteroneProgesterone, Micronized | 111 | $6,088 |
| Tadalafil | 27 | $4,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mannkind CorporationAfrezza | $410 | $139,51840 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $357 | $102,06475 claims |
| Boehringer IngelheimJardiance | $20 | $77,19755 claims |
| Novo NordiskOzempic | $361 | $68,98541 claims |
| Johnson & JohnsonXarelto, Procrit | $37 | $52,16229 claims |
| AstraZenecaFarxiga | $558 | $25,91618 claims |
| AbbVieSynthroid | $1,046 | $1,85630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.